Vladimir Coric

USPTO Granted Patents = 16 (Patent Applications = 29)

EPO Patents = 7 (Patent Applications = 21)

Average Co-Inventor Count = 2.2

ph-index = 1

Forward Citations = 7(Granted Patents)

Company Filing History:

8 out of 28

Biohaven Therapeutics Ltd.

patents

3 out of 3,681

Bristol-myers Squibb Compnay

patents

3 out of 45

Celldex Therapeutics Limited

Biohaven Pharmaceutical Ireland Dac

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383619 - Use of glutamate modulating agents with immunotherapies to treat cancer (2025-08-12),

2. 12364687 - Use of riluzole oral disintegrating tablets for treating diseases (2025-07-22),

3. 12201618 - Use of riluzole prodrugs to treat Alzheimer's disease (2025-01-21),

4. 12161633 - Use of riluzole prodrugs to treat alzheimer's disease (2024-12-10),

5. 12121609 - Sublingual formulation of riluzole (2024-10-22),

6. 12102618 - Use of riluzole prodrugs to treat ataxias (2024-10-01),

7. 11965031 - Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment (2024-04-23),

8. 11660267 - Sublingual formulation of riluzole (2023-05-30),

9. 11554117 - Glutamate agents in the treatment of mental disorders (2023-01-17),

10. 11400155 - Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers (2022-08-02),

11. 11083724 - Rimegepant for CGRP related disorders (2021-08-10),

12. 10668152 - Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment (2020-06-02),

13. 10392442 - Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment (2019-08-27),

14. 10052318 - Glutamate agents in the treatment of mental disorders (2018-08-21),

15. 8778979 - Glutamate agents in the treatment of mental disorders (2014-07-15),

Title: The Innovative Contributions of Vladimir Coric

Introduction

Vladimir Coric is a prominent inventor based in Madison, Connecticut, known for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, he has made remarkable strides in developing innovative treatments for various diseases, particularly cancer.

Latest Patents

Among his latest patents, Coric has disclosed methods for treating cancer using a combination of immunotherapeutic agents and glutamate modulating agents. This includes the use of agents such as riluzole or trigriluzole in conjunction with PD-1, PD-L1, or CTLA-4 checkpoint inhibitors. Additionally, he has developed methods for treating diseases with riluzole oral disintegrating tablets, which involve administering a therapeutically effective amount of riluzole in a fast-dispersing dosage form.

Career Highlights

Coric has worked with notable companies in the pharmaceutical industry, including Biohaven Therapeutics Ltd. and Bristol-Myers Squibb Company. His work has focused on advancing therapeutic options that enhance patient outcomes through innovative drug formulations and combinations.

Collaborations

Throughout his career, Coric has collaborated with esteemed colleagues such as Robert Berman and Tibor P. Keler. These partnerships have contributed to the development of groundbreaking therapies and have furthered research in the field.

Conclusion

Vladimir Coric's innovative work in pharmaceuticals, particularly in cancer treatment, showcases his dedication to improving healthcare through scientific advancements. His numerous patents reflect his commitment to finding effective solutions for complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.